The global tally of confirmed coronavirus cases hit 60 million on Nov. 25, with the pace of new infections accelerating and the United States reporting record numbers of hospitalizations, according to a Reuters tally.

Global coronavirus infections exceeded 50 million, according to a Reuters tally, with a second wave of the virus in the past 30 days accounting for a quarter of the total.

Europe’s new Covid-19 cases doubled in five weeks, propelling the region across the bleak milestone of 10 million total infections, according to a Reuters tally.

Europe’s reported coronavirus cases more than doubled in 10 days, crossing 200,000 daily infections for the first time according to a Reuters tally, with many Southern European countries reporting their highest single-day cases.

Germany’s CureVac NV started a mid-stage study testing the company’s experimental coronavirus vaccine and plans to begin a decisive global trial with about 30,000 volunteers in the fourth quarter of 2020.

Will the solitary path the United States is on, insulate it from further Covid-19 pandemic-related damage? Christopher Snyder, a professor of economics at Dartmouth University, believes the answer depends largely on the eventual vaccine’s level of efficacy.

Several large U.S. states are not heeding new federal health officials’ calls to reduce Covid-19 testing of some exposed to the virus, joining a broad rebuke of the Trump administration by public health leaders.

Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering.

German biotech firm BioNTech and U.S. drugmaker Pfizer reported additional data showing their experimental Covid-19 vaccine was safe and induced an immune response in patients.

Unlisted German biotech firm CureVac will become the second company after rival BioNTech to launch human trials of an experimental coronavirus vaccine in the country, eyeing a potential approval in mid-2021.